Featured Clinical Trial:

Hepatocellular carcinoma (product/compound: Sunitinib; Sorafenib)

ClinicAid Locations: Southern California – Fountain Valley

Status: Enrollment closed.

Condition: Hepatocellular Carcinoma

Product Name/Compound: Sunitinib; Sorafenib

Full Study Title: A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Study Summary: The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.

Eligible Participants:

Inclusion (Eligible):

• Histologically-confirmed diagnosis of hepatocellular carcinoma
• presence of measurable disease by radiographic imaging
• Child-Pugh class A
• ECOG PS 0 or 1
• Adequate organ function

Exclusion (Not Eligible):

• Prior treatment with any systemic treatment for hepatocellular carcinoma
• Prior local treatment within 4 weeks from entry
• Presence of clinically relevant ascites
• Severe hemorrhage < 4 weeks of starting study treatment
• Known HIV or serious acute or chronic illness
• Current treatment on another clinical trial
• Pregnancy or breastfeeding

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT00699374

<< Back to all ClinicAid clinical trials